Episode 4: Individualizing Treatment in Rheumatoid Arthritis: The Crucial Impact of Patient Heterogeneity

Update: 2008-12-05

Description

Professor VonVollenhoven discusses factors which distinguish individual responses by patients with rheumatoid arthritis to various anti-TNF agents. He describes observations of radiologic and clinical progression of illness in subgroups of patients and provides an overview of considerations in choosing one pharmacologic agent over another. Professor VonVollenhoven also discusses recent research on the role of biologic markers for RA.

Comments

In Channel

Episode 6: Individualizing Therapy: Today’s Options, Tomorrow’s Opportunities

2009-03-0619:02

Episode 5: Progress and Prognosis: Evaluating Patients' Responses to Biologic Therapy

2009-02-0616:18

Episode 4: Individualizing Treatment in Rheumatoid Arthritis: The Crucial Impact of Patient Heterogeneity

2008-12-0514:21

Episode 3: Anti-TNF Treatment: Focus on early Rheumatoid Arthritis. Featuring an interview with Professor Paul Emery

2008-10-0314:21

Episode 2: Establishing the Evidence: Clinical Trials with TNF Inhibitors

2008-08-2714:53

Episode 1: TNF-Alpha: Concept to Proof of Concept

2008-05-3014:53

00:00

Episode 4: Individualizing Treatment in Rheumatoid Arthritis: The Crucial Impact of Patient Heterogeneity

Rheumatology News International

#box-pro-ellipsis-176126489401416{-webkit-line-clamp:2;}Episode 4: Individualizing Treatment in Rheumatoid Arthritis: The Crucial Impact of Patient Heterogeneity

Episode 4: Individualizing Treatment in Rheumatoid Arthritis: The Crucial Impact of Patient Heterogeneity

Rheumatology News International

Episode 4: Individualizing Treatment in Rheumatoid Arthritis: The Crucial Impact of Patient Heterogeneity